Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision | Next revisionBoth sides next revision | ||
content:aicardi-goutieres_syndrome [2020/02/21 07:30] – [References] bijuhameed | content:aicardi-goutieres_syndrome [2022/04/30 11:31] – administrator@icnapedia.org | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Aicardi-Goutières syndrome ====== | ====== Aicardi-Goutières syndrome ====== | ||
- | Aicardi-Goutieres syndrome (AGS) is a genetic encephalopathy characterized by the inappropriate induction of a type I interferon-mediated immune response and usually results in severe cognitive and physical morbidities. It is named after [[icnapedia> | + | Aicardi-Goutieres syndrome (AGS) is a genetic encephalopathy characterized by the inappropriate induction of a type I interferon-mediated immune response and usually results in severe cognitive and physical morbidities. It is named after [[icnapedia> |
===== Clinical features ===== | ===== Clinical features ===== | ||
There are two distinct forms of the syndrome: | There are two distinct forms of the syndrome: | ||
Line 18: | Line 18: | ||
* startle reaction to sudden noise | * startle reaction to sudden noise | ||
* no further worsening of the disease once the symptoms lessen | * no further worsening of the disease once the symptoms lessen | ||
- | * 50% - 75% of patients with AGS develop focal and generalized seizures, which are sometimes refractory to treatment[(: | + | * 50% - 75% of patients with AGS develop focal and generalized seizures, which are sometimes refractory to treatment[(: |
However the clinical features can be quite heterogenous. The neurological dysfunction is not always severe and need not even be present at all. Other features originally described including microcephaly, | However the clinical features can be quite heterogenous. The neurological dysfunction is not always severe and need not even be present at all. Other features originally described including microcephaly, | ||
===== Genetics ===== | ===== Genetics ===== | ||
- | AGS is a genetically heterogeneous disease. Most cases of AGS are inherited in an autosomal recessive manner. However it can also be autosomal dominant with heterozygous mutations in TREX, ADAR, or IFIH1 genes. In some cases AGS-associated mutations show incomplete penetrance with children in the same family with the same mutations showing markedly different neurological and developmental outcomes[(: | + | AGS is a genetically heterogeneous disease. Most cases of AGS are inherited in an autosomal recessive manner. However it can also be autosomal dominant with heterozygous mutations in TREX, ADAR, or IFIH1 genes. In some cases AGS-associated mutations show incomplete penetrance with children in the same family with the same mutations showing markedly different neurological and developmental outcomes[(: |
To date AGS has been associated with mutations of seven different genes. | To date AGS has been associated with mutations of seven different genes. | ||
^ Type ^ OMIM | Gene | Locus | Frequency | ^ Type ^ OMIM | Gene | Locus | Frequency | ||
Line 33: | Line 33: | ||
| AGS7 | [[omim> | | AGS7 | [[omim> | ||
- | The late onset form is observed most commonly in the context of mutations in RNASEH2B, SAMHD1 and ADAR1 while mutations in TREX1, RNASEH2A and RNASEH2C, mimic the sequelae of congenital, transplacentally acquired infection[(: | + | The late onset form is observed most commonly in the context of mutations in RNASEH2B, SAMHD1 and ADAR1 while mutations in TREX1, RNASEH2A and RNASEH2C, mimic the sequelae of congenital, transplacentally acquired infection[(: |
===== Pathophysiology ===== | ===== Pathophysiology ===== | ||
[{{ : | [{{ : | ||
- | Both AGS and many placentally acquired viral infections are characterized by the production of high levels of IFNα. Astrocyte-specific chronic overproduction of IFNα in transgenic mice has been shown to recapitulate the neuropathologic findings seen in AGS[(: | + | Both AGS and many placentally acquired viral infections are characterized by the production of high levels of IFNα. Astrocyte-specific chronic overproduction of IFNα in transgenic mice has been shown to recapitulate the neuropathologic findings seen in AGS[(: |
- | The actual pathomechanisms that lead to CNS damage in AGS patients are unknown. In a mouse model transgenic for a glial fibrillary acidic protein-interferon-alpha fusion protein (GFAP-IFN-< | + | The actual pathomechanisms that lead to CNS damage in AGS patients are unknown. In a mouse model transgenic for a glial fibrillary acidic protein-interferon-alpha fusion protein (GFAP-IFN-< |
- | Interferonopathies comprise an expanding group of monogenic diseases characterised by disturbance of the homeostatic control of interferon (IFN)-mediated immune responses[(: | + | Interferonopathies comprise an expanding group of monogenic diseases characterised by disturbance of the homeostatic control of interferon (IFN)-mediated immune responses[(: |
Line 47: | Line 47: | ||
* AGS is difficult to diagnose since many of the symptoms are similar to those of other disorders | * AGS is difficult to diagnose since many of the symptoms are similar to those of other disorders | ||
* Diagnosis is based on the clinical symptoms of the disease | * Diagnosis is based on the clinical symptoms of the disease | ||
- | * Radiological abnormalities include basal ganglia calcification (usually bilateral) involving globus pallidus, putamen, caudate nucleus, and dentate nuclei. It may also extend to the periventricular white matter; increased signal on T2 weighted brain MRI particularly in the frontotemporal region along with cerebral atrophy[(: | + | * Radiological abnormalities include basal ganglia calcification (usually bilateral) involving globus pallidus, putamen, caudate nucleus, and dentate nuclei. It may also extend to the periventricular white matter; increased signal on T2 weighted brain MRI particularly in the frontotemporal region along with cerebral atrophy[(: |
* Cerebrospinal fluid (CSF) shows increased levels of lymphocytes indicating chronic lymphocytosis in the absence of evidence of infection. | * Cerebrospinal fluid (CSF) shows increased levels of lymphocytes indicating chronic lymphocytosis in the absence of evidence of infection. | ||
* Raised interferon < | * Raised interferon < | ||
Line 57: | Line 57: | ||
* Treatment may have to be continued beyond the subacute encephalopathic phase in cases where chilblains are a particular problem | * Treatment may have to be continued beyond the subacute encephalopathic phase in cases where chilblains are a particular problem | ||
* immune-modulating therapies have been tried empirically including prednisone with azathioprine, | * immune-modulating therapies have been tried empirically including prednisone with azathioprine, | ||
- | * Anti-interferon alpha antibody therapy: blocking interferon alpha activity using monoclonal antibodies is currently under consideration and clinical trials are currently underway in SLE[(: | + | * Anti-interferon alpha antibody therapy: blocking interferon alpha activity using monoclonal antibodies is currently under consideration and clinical trials are currently underway in SLE[(: |
* Reverse transcriptase inhibitors (RTIs) (compounds that can potentially disrupt the replication cycle of both exogenous retroviruses and endogenous retro-elements) are of potential interest in treating AGS. RTIs are already prescribed in children and adults with HIV-1 infection[(: | * Reverse transcriptase inhibitors (RTIs) (compounds that can potentially disrupt the replication cycle of both exogenous retroviruses and endogenous retro-elements) are of potential interest in treating AGS. RTIs are already prescribed in children and adults with HIV-1 infection[(: | ||
* Agents that deplete B cells are also potential therapeutic agents since AGS is associated with lymphocytes and autoantibody production | * Agents that deplete B cells are also potential therapeutic agents since AGS is associated with lymphocytes and autoantibody production |